Robert W. Duggan Acquires 56,054 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc. (NASDAQ:PLSE) Director Robert W. Duggan acquired 56,054 shares of the firm’s stock in a transaction on Wednesday, December 11th. The shares were bought at an average cost of $17.35 per share, with a total value of $972,536.90. Following the completion of the acquisition, the director now directly owns 42,228,057 shares in the company, valued at approximately $732,656,788.95. This represents a 0.13 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Pulse Biosciences Stock Up 3.0 %

Shares of PLSE traded up $0.51 during mid-day trading on Friday, reaching $17.65. 314,720 shares of the stock traded hands, compared to its average volume of 200,806. Pulse Biosciences, Inc. has a 1 year low of $6.59 and a 1 year high of $22.69. The firm has a fifty day moving average price of $17.68 and a 200 day moving average price of $16.40.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same period last year, the company earned ($0.19) EPS.

Institutional Trading of Pulse Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Pulse Biosciences by 28.8% in the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock worth $7,379,000 after acquiring an additional 189,227 shares during the period. Price T Rowe Associates Inc. MD purchased a new stake in shares of Pulse Biosciences in the 1st quarter worth approximately $88,000. Cetera Advisors LLC purchased a new stake in shares of Pulse Biosciences during the 1st quarter worth $109,000. Bank of New York Mellon Corp boosted its stake in Pulse Biosciences by 23.4% in the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock valued at $570,000 after acquiring an additional 9,639 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in Pulse Biosciences by 6.7% during the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock worth $288,000 after buying an additional 1,608 shares during the last quarter. 76.95% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a research note on Thursday.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.